<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Best evidence statement (BESt). Treatment of children and adolescents with major depressive disorder (MDD) during the acute phase.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Treatment of children and adolescents with major depressive disorder (MDD) during the acute phase. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010 Jan. 11 p.  [43 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Behavior therapy  (94.33); Lithium therapy  (94.22); Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior  (296.33); Major depressive affective disorder, single episode, severe, without mention of psychotic behavior  (296.23); Supportive verbal psychotherapy  (94.38)"/><FieldValue Value="MSH: Acute Disease ; Antidepressive Agents ; Antidepressive Agents, Second-Generation ; Behavior Therapy ; Bupropion ; Citalopram ; Cognitive Therapy ; Combined Modality Therapy ; Cyclohexanols ; Depressive Disorder, Major ; Fluoxetine ; Lithium ; Mianserin ; Paroxetine ; Psychotherapy ; Risperidone ; Serotonin Uptake Inhibitors ; Sertraline "/><FieldValue Value="MTH: Antidepressive Agents ; Bupropion ; Cognitive Therapy ; Combined Modality Therapy ; follow-up ; Lithium ; MAJOR DEPRESSIVE DISORDER ; Mirtazapine ; Patient Monitoring ; Psychotherapy ; Selective Serotonin Reuptake Inhibitors ; Serotonin Uptake Inhibitors ; Supportive verbal psychotherapy "/><FieldValue Value="PDQ: fluoxetine ; sertraline ; venlafaxine "/><FieldValue Value="SNOMEDCT_US: Acute disease  (2704003); Antidepressant  (36236003); Antidepressant  (372720008); Behavioral therapy  (166001); Bupropion  (387564004); Bupropion  (96199001); Citalopram  (321986007); Citalopram  (372596005); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Depression management program  (401174001); Duloxetine  (407032004); Duloxetine  (407033009); Escitalopram  (395246009); Escitalopram  (400447003); Fluoxetine  (372767007); Fluoxetine  (53640004); Interpersonal psychotherapy  (443730003); Lithium  (321719003); Lithium  (85899009); Lithium therapy  (68852009); Major depressive disorder  (370143000); Mianserin  (387565003); Mianserin  (96200003); Mirtazapine  (108430001); Mirtazapine  (386847004); Monitoring of patient  (182777000); Paroxetine  (321963000); Paroxetine  (372595009); Psychotherapy  (75516001); Quetiapine  (108443001); Quetiapine  (386850001); Risperidone  (108386000); Risperidone  (386840002); Selective serotonin re-uptake inhibitor  (349854005); Selective serotonin re-uptake inhibitor  (373225007); Sertraline  (321958004); Sertraline  (372594008); Severe major depression, single episode, without psychotic features  (76441001); Severe recurrent major depression without psychotic features  (36474008); Supportive verbal psychotherapy  (85925008); Venlafaxine  (108432009); Venlafaxine  (372490001)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Major depressive disorder during the acute phase&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Assessment of Therapeutic Effectiveness" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Pediatrics" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate which pharmacotherapies and psychotherapies, compared to placebo, improve symptoms and functionality in family, educational and social domains among children and adolescents 6 to 17 years of age diagnosed with major depressive disorder (MDD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Children and adolescents 6 to 17 years of age diagnosed with major depressive disorder (MDD)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Excluding children with bipolar disorders, psychotic disorders, and schizophrenia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Supportive psychotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Depression specific therapy (DST) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cognitive behavioral therapy (CBT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpersonal psychotherapy (IPT) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressants/selective serotonin reuptake inhibitors (SSRIs) alone or with psychotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Fluoxetine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Escitalopram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Citalopram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sertraline &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Paroxetine (adolescents only &amp;ndash; not approved for children) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lithium &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Quetiapine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bupropion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mirtazapine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Risperidone &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Venlafaxine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Duloxetine &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring and follow-up &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Symptoms of depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Functionality in family, educational, and social domains &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Search Strategy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Original Search&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;depression.mp. &lt;strong&gt;OR&lt;/strong&gt; major depression.mp. &lt;strong&gt;OR&lt;/strong&gt; exp Depressive Disorder, Major/Antidepressant and each individual antidepressant and drug: Fluoxetine, Citalopram, Sertraline, Escitalopram, Paroxetine, Lithium, Bupropion, Mirtazapine, Risperidone, and Venlafaxine&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Selective Serotonin Reuptake Inhibitors (SSRIs)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Cognitive Behavioral Therapy (CBT) or Interpersonal Psychotherapy (IPT)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Limits&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;English language &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&quot;child (6 to 12 years)&quot; or &quot;adolescent (13 to 18 years)&quot;) &lt;br /&gt;&#xD;&#xA;        &lt;strong&gt;OR&lt;/strong&gt; &lt;em&gt;pediatr$&lt;/em&gt;/* &lt;strong&gt;OR&lt;/strong&gt; &lt;em&gt;child$&lt;/em&gt;/* &lt;strong&gt;OR&lt;/strong&gt; &lt;em&gt;adolesc $&lt;/em&gt;/* &lt;strong&gt;OR&lt;/strong&gt; &lt;em&gt;teen $&lt;/em&gt;/* &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;(guideline or meta analysis or practice guidelines or systematic review).pt. or &quot;the cochrane library&quot;.jn. or &quot;cochrane database of systematic reviews&quot;.jn. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Additional articles&lt;/strong&gt; &amp;ndash; identified from reference lists, systematic reviews, and clinicians&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is a lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to the patients (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was reviewed by Cincinnati Children's Hospital Medical Center Evidence Federation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of the evidence (1a-5) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;All Major Depressive Disorder (MDD) Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the severity (brief, uncomplicated, mild, moderate or severe) of the child's or adolescent's MDD be the basis of the treatment decision (Brent et al., 2008 [2a]; Local Consensus [5]; Hughes et al., 2007 [5a]). (See algorithm in the Appendix in the original guideline document) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Brief or Mild/Uncomplicated MDD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that supportive therapy be the initial treatment for children and adolescents with brief, uncomplicated and/or mild depression continuing for 4 to 8 sessions until remission (Brent et al., 2008 [2a]; Local Consensus [5]; Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a])&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Supportive Psychotherapy &amp;ndash; Includes but not limited to active listening and reflection, restoration of hope, problem solving, coping skills, and strategies for maintaining participation in treatment, psychoeducation, and family and school involvement (Birmaher et al., 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: It is not warranted to prescribe antidepressant medication for the initial treatment of children and young people with mild depression (Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended for non-responders to supportive therapy that psychotherapy and/or pharmacotherapy be offered/trialed in children and adolescents with mild depression. Possible therapies are:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Depression specific therapy (Local Consensus [5]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cognitive behavioral therapy (CBT) or &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpersonal psychotherapy (IPT) &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;(Klein, Jacobs, &amp;amp; Reinecke, 2007 [1a]; Brent et al., 2008 [2a]; Local Consensus [5]; Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Psychotherapy appears to be more effective for youth ages 12 to 18 years (Watanabe et al., 2007 [1b]).&lt;/p&gt;&#xD;&#xA;    &lt;/blockquote&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;        &lt;li&gt;Antidepressant/selective serotonin reuptake inhibitor (SSRI) monotherapy (fluoxetine, escitalopram, citalopram, or sertraline) alone or with psychotherapy (Williams et al., 2009 [1a]; Brent et al., 2008 [2a]; Local Consensus [5]; Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Avoid antidepressant medication for initial treatment for children and adolescents with mild depression (National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Begin antidepressants/SSRIs at lowest dose, titrating up and down based upon effectiveness and tolerance of side effects (Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: Treatment with antidepressants may be administered alone until the child is amenable to psychotherapy or treatment can be combined from the beginning if appropriate (Birmaher et al., 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Moderate or Severe MDD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended children and adolescents with moderate or severe MDD begin antidepressants/SSRIs as first-line treatment with the addition of Depression Specific Therapy, Cognitive Behavioral Therapy, or Interpersonal Psychotherapy as clinically necessary.&#xD;&#xA;    &lt;p&gt;Possible antidepressants are:&lt;/p&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Fluoxetine (Hetrick et al., 2007 [1a]; Wallace et al., 2006 [1a]; Whittington et al., 2004 [1b]; March et al., 2004 [2a]; US Preventive Services Task Force, 2009 [5a]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Escitalopram (Local Consensus [5]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Citalopram (Williams et al., 2009 [1a]; Wallace et al., 2006 [1a]; Cheung, Emslie, &amp;amp; Mayes, 2005 [1a]; Cheung, Emslie, &amp;amp; Mayes, 2006 [1b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sertraline (Hetrick et al., 2007 [1a]; Cheung, Emslie, &amp;amp; Mayes, 2005 [1a]; Whittington et al., 2004 [1b]) &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;(Hetrick et al., 2007 [1a]; Cheung, Emslie, &amp;amp; Mayes, 2005 [1a]; Brent et al., 2008 [2a]; Cheung et al., 2008 [3b]; Ambrosini et al., 1999 [4b]; Local Consensus [5]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Combined psychotherapy with fluoxetine has been effective for some adolescents (Williams et al., 2009 [1a]; Kratochvil et al., 2006 [2a]; March et al., 2004 [2a]; US Preventive Services Task Force, 2009 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Medication choice is collaborative decision/agreement between clinician, patient, and family, based upon such things as patient/family history, preferences, response to medication(s), and other considerations. (Hughes et al., 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: Begin SSRIs at lowest dose, titrating upward and back down based upon effectiveness and tolerance of side effects (Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 4&lt;/strong&gt;: When a patient responds to medication(s) with symptom remission, maintain treatment for 6 months (Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/blockquote&gt;&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that medication dosage be lowered or medication switch to one of the following alternate antidepressant/SSRI if patient does not experience adequate clinical improvement or have satisfactory symptom response or medication tolerance to initial antidepressant/SSRI treatment. Alternate antidepressants/SSRIs include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Fluoxetine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Citalopram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sertraline &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Escitalopram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Paroxetine (adolescents only &amp;ndash; not approved for children) (Cheung, Emslie, &amp;amp; Mayes, 2005 [1a]; Berard et al., 2006 [2a]; Keller et al., 2001 [2a]) &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;(Whittington et al., 2004 [1b]; Local Consensus [5]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that treatment be augmented with one of the following for children and adolescents showing only a partial response to SSRI treatment and/or having not yet achieved remission:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lithium (Nierenberg et al., 2006 [2a]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Quetiapine (Olver et al., 2008 [4b]; Pathak et al., 2005 [4b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bupropion (Glod et al., 2003 [3b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mirtazapine (Haapasalo-Pesu et al., 2004 [3b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Risperidone (Local Consensus [5]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Venlafaxine (benefit among adolescents not children) (Cheung, Emslie, &amp;amp; Mayes, 2006 [1b]; Emslie et al., 2007 [2a]) &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;(Emslie et al., 2007 [2a]; Local Consensus [5]; Hughes et al., 2007 [5a])&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Or switch to one of the following along with Depression Specific Therapy/Cognitive Behavioral Therapy:&lt;/p&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Bupropion (Glod et al., 2003 [3b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mirtazapine (Haapasalo-Pesu et al., 2004 [3b]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Venlafaxine (benefit among adolescents not children) (Cheung, Emslie, &amp;amp; Mayes, 2006 [1b]; Emslie et al., 2007 [2a]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Duloxetine &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;(Brent et al., 2008 [2a]; Local Consensus [5]; Hughes et al., 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;All MDD Patients on Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended patients taking antidepressants/SSRIs be closely monitored by health care providers, family and caregivers for emergent suicidality, hostility, agitation, mania, and unusual changes in behavior, especially within the first few months of treatment or when dosage is adjusted (Lock et al., 2005 [5]; Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: A balance of benefit and harm includes consideration that treatment with antidepressants decreases the likelihood of actual suicides even though an increase in suicide behavior and thoughts has been documented in clinical trials (Williams et al., 2009 [1a]; Bridge et al., 2007 [1a]; Lock et al., 2005 [5]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that once a patient responds and achieves depressive symptom remission, medication be continued at least 6 to 12 months at full therapeutic dose and be seen at least every 3 months during continuation of treatment to monitor for relapse and suicide ideation (Nierenberg et al., 2006 [2a]; Cheung et al., 2008 [3b]; Hughes et al., 2007 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that antidepressants, except fluoxetine, be discontinued slowly (Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that tricycle antidepressants not be used in children and adolescents (Bauer et al., 2002 [5]; Birmaher et al., 2007 [5a]; Hughes et al., 2007 [5a]; National Collaborating Centre for Mental Health, 2005 [5a]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is a lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to the patients (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A clinical algorithm is provided in the original guideline document for the treatment of major depressive disorder (MDD).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ambrosini PJ, Wagner KD, Biederman J, Glick I, Tan C, Elia J, Hebeler JR, Rabinovich H, Lock J, Geller D. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):566-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10230188&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ, World Federation of Societies of Biological Psychiatry (WFSBF) Task Force. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders [trunc]. World J Biol Psychiatry. 2002 Apr;3(2):69-86. [160 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12479080&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):59-75. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16553529&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Birmaher B, Brent D, AACAP Work Group on Quality Issues, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18049300&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral  therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27;299(8):901-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18314433&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17440145&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cheung A, Kusumakar V, Kutcher S, Dubo E, Garland J, Weiss M, Kiss A, Levitt A. Maintenance study for adolescent depression. J Child Adolesc Psychopharmacol. 2008 Aug;18(4):389-94. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18759650&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005 Jul;46(7):735-54. [32 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15972068&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ. 2006 Jan 17;174(2):193-200. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16415467&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2007 Apr;46(4):479-88. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17420682&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs. 2003 Jul-Sep;16(3):123-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14603988&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol. 2004 Summer;14(2):175-84. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15319015&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004851. [127 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17636776&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, Jensen P, Curry J, Vitiello B, Lopez M, Shon SP, Pliszka SR, Trivedi MH, Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):667-86. [131 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17513980&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7):762-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11437014&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1403-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18049290&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, Reinecke M, Vitiello B, Rohde P, Feeny N, Casat C, Pathak S, Weller E, May D, Mayes T, Robins M, March J, TADS Team. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1412-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17135986&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lock J, Walker LR, Rickert VI, Katzman DK, Society for Adolescent Medicine. Suicidality in adolescents being treated with antidepressant medications and the  black box label: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2005 Jan;36(1):92-3. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15702497&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J, Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004 Aug 18;292(7):807-20. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15315995&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Collaborating Centre for Mental Health. Depression in children and young people. Identification and management in primary, community and secondary care. London (UK): National Institute for Health Clinical Excellence (NICE); 2005 Sep. 68 p.&amp;nbsp;(Clinical guideline; no. 28).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006 Sep;163(9):1519-30; quiz 1665. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16946176&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR. Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol. 2008 Dec;23(8):653-60. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18816504&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol. 2005 Aug;15(4):696-702. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16190801&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics. 2009 Apr;123(4):1223-8. [6 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336383&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wallace AE, Neily J, Weeks WB, Friedman MJ. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):37-58. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16553528&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Watanabe N, Hunot V, Omori IM, Churchill R, Furukawa TA. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatr Scand. 2007 Aug;116(2):84-95. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17650269&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004 Apr 24;363(9418):1341-5. [29 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15110490&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Williams SB, O'Connor EA, Eder M, Whitlock EP. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2009 Apr;123(4):e716-35. [88 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336361&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate acute phase treatment that produces a symptomatic response and ultimately full symptom remission with treatment maintenance to help avoid relapse and reoccurrence of another episode &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;60% of children and adolescents with major depressive disorder (MDD) respond to placebo, indicating any level of care provides positive outcome. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;15% to 30% respond to brief supportive treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs) are an effective treatment for adolescent depression. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Supportive therapy is effective for mild major depressive disorder (MDD) as is cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients are more likely to benefit from antidepressant treatment than commit suicide; risk and benefit need to be weighed by clinicians due to the risk of suicide ideation tied to selective serotonin reuptake inhibitors (SSRIs). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All treatment arms of the Treatment for Adolescents with Depression Study (TADS) were effective in reducing suicide ideations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;During the 1990s the number of suicides decreased among youths in the United States as the number of antidepressant prescriptions increased. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CBT appears to minimize persistent suicidal ideations and behaviors. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressants/SSRIs have been well tolerated by pediatric population with few short-term side effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Events&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse events for selective serotonin reuptake inhibitors (SSRIs) include suicide ideations &amp;ndash; passive thoughts about wanting to be dead or active thoughts about killing oneself, not accompanied by preparatory behavior, yet no suicide deaths occurred in any of the trials of this systematic review. Patients treated with fluoxetine therapy show more clinically significant suicidal ideation than those treated with cognitive behavioral therapy (CBT) or combination, CBT and fluoxetine. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Overall SSRIs were well tolerated with the main side effects including headache, diarrhea, nausea, vomiting, fatigue, insomnia, agitation, irritability and behavioral changes (anxiety, hostility and impulsivity). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Side effects can be addressed with dose titration or medication change and appear to subside with time. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risks&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Increased risk of suicide which is the 3rd leading cause of death among those 15 to 24 years of age and 6th leading cause of death among those 5 to 14 years of age. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treating youth with antidepressants leads to a 1% to 3% increase in suicidal ideation and/or behavior. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Difficulty differentiating disease process from adverse events of treatments, including medications when suicide attempts are made while on SSRIs and difficulty drawing conclusions about the association between suicide related events and SSRIs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Since the Food and Drug Administration's (FDA's) &quot;black box warning,&quot; the number of SSRI prescriptions decreased and the number of suicides increased. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients may be at risk for relapse and need to be assessed for residual symptoms of depression. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive practice guideline. These recommendations result from review of literature and practices current at the time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current revision of this document. This document is not intended to impose standards of care preventing selective variances from the recommendations to meet the specific and unique requirements of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Treatment of children and adolescents with major depressive disorder (MDD) during the acute phase. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010 Jan. 11 p.  [43 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Jan 1" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Cincinnati Children's Hospital Medical Center - Hospital/Medical Center" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cincinnati Children's Hospital Medical Center&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Development Group&lt;/em&gt;: Michael Sorter, MD, Director Division of Child &amp;amp; Adolescent Psychiatry; Robert Kowatch, MD, PhD, Division of Child &amp;amp; Adolescent Psychiatry; Sergio Delgado, MD, Division of Child &amp;amp; Adolescent Psychiatry; Carol Engel, MD, Division of Child &amp;amp; Adolescent Psychiatry; Mary Matias Akhter, MD, Division of Child &amp;amp; Adolescent Psychiatry; Amanda Matthias, LISW, Division of Child &amp;amp; Adolescent Psychiatry&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88019&amp;amp;libID=87707&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Judging the strength of a recommendation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Jan. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/d7344329-03d0-45f3-b6ca-02c746a472ec.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Grading a body of evidence to answer a clinical question. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/bd6f4eea-825c-49c3-a0e5-3e66c54dc066.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table of evidence levels. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Feb 29. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/5ce396bf-fdcb-4c65-a9f2-1b9888d4fc7e.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also, the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=88019&amp;amp;libID=87707&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt; contains applicability issues to measure potential outcomes.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on December 9, 2010. This summary was updated by ECRI Institute on May 20, 2011 following the U.S. Food and Drug Administration advisory on antipsychotic drugs. This summary was updated by ECRI Institute on September 12, 2011 following the U.S. Food and Drug Administration advisory on Celexa (citalopram hydrobromide). This summary was updated by ECRI Institute on April 16, 2012 following the updated U.S. Food and Drug Administration advisory on Celexa (citalopram hydrobromide).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original full-text guideline, which is subject to the following copyright restrictions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Copies of this &lt;a href=&quot;http://www.cincinnatichildrens.org/svc/alpha&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center (CCHMC)&lt;/a&gt; Best Evidence Statement (BESt) are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Examples of approved uses of the BESt include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to anyone involved in the organization's process for developing and implementing evidence based care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlinks to the CCHMC website may be placed on the organization's website &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or electronic documents &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to patients and the clinicians who manage their care &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Notification of CCHMC at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt; for any BESt adopted, adapted, implemented or hyperlinked by the organization is appreciated.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
